Literature DB >> 19629630

Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

Wei Xu1, Xin Cao1, Kou-Rong Miao1, Chun Qiao1, Yu-Jie Wu1, Qiong Liu1, Lei Fan1, Jian-Yong Li2.   

Abstract

Chronic lymphocytic leukemia (CLL) shows a remarkable heterogeneity, with some patients having an almost normal lifespan, others surviving only several months after diagnosis despite intensive therapy. The aim of this study was to investigate the serum thymidine kinase 1 (TK1) concentration in Chinese patients with CLL and its correlation with well-established other prognostic factors. Enhanced chemiluminescent dot blot assay was performed to measure serum TK1 concentration in 80 CLL patients. The concentration of TK1 was significantly increased in patients with Binet C (P = 0.002), higher levels of serum lactate dehydrogenase (LDH) (P = 0.012) and beta2-microglobulin (beta2-MG) (P = 0.025), unmutated IGHV status (P < 0.001), or higher expression levels of ZAP-70 (P = 0.014) and CD38 (P = 0.018) groups compared to the patients with Binet A, lower levels of serum LDH and beta2-MG, mutated IGHV status, or lower expression levels of ZAP-70 and CD38 groups, respectively. Strong correlation of TK1 level with IGHV mutations (r = 0.412, P < 0.001) or ZAP-70 (r = 0.263, P = 0.024) was observed. According to receiver operating characteristic curve analysis for serum TK1 concentration and IGHV mutational status, area under the curve was 0.757 (P = 0.001) and the optimal cut-off value of serum TK1 concentration level was 1.75 pM, with a 87.8% specificity, a 63.6% sensitivity. It was showed that serum TK1 concentration could be a predictive marker of IGHV mutational status, and might be applied for the assessment of prognosis in patients with CLL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629630     DOI: 10.1007/s12185-009-0380-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

Authors:  C Magnac; R Porcher; F Davi; J Nataf; B Payelle-Brogard; R P Tang; P Oppezzo; V Lévy; G Dighiero; F Ajchenbaum-Cymbalista
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

2.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis.

Authors:  M G Kauffman; T J Kelly
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

3.  Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation.

Authors:  Q He; S Skog; N Wang; S Eriksson; B Tribukait
Journal:  Eur J Cell Biol       Date:  1996-06       Impact factor: 4.492

4.  Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.

Authors:  Qimin He; Pinggn Zhang; Li Zou; Hongxun Li; Xiuqin Wang; Shan Zhou; Tommy Fornander; Sven Skog
Journal:  Oncol Rep       Date:  2005-10       Impact factor: 3.906

5.  Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  R Luoni; G Ucci; A Riccardi; P Gobbi; F M Avato; C Vignale; E Ascari
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

6.  CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia.

Authors:  Wei Xu; Jian-Yong Li; Yu-Jie Wu; Hui Yu; Qiu-Dan Shen; Tian Tian; Li Li; Hong-Xia Qiu
Journal:  Leuk Res       Date:  2008-07-31       Impact factor: 3.156

7.  Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.

Authors:  S Suki; F Swan; S Tucker; H A Fritsche; J R Redman; M A Rodriguez; P McLaughlin; J Romaguera; F B Hagemeister; W S Velasquez
Journal:  Leuk Lymphoma       Date:  1995-06

8.  Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation.

Authors:  Hong-Xia Qiu; Wei Xu; Xiang-Shan Cao; Min Zhou; Yun-Feng Shen; Yan-Li Xu; Xue-Mei Sun; Qiong Liu; Rong Wang; Hai-Rong Qiu; Ji-Shi Wang; Jian-Yong Li
Journal:  Leuk Lymphoma       Date:  2008-10

9.  Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway.

Authors:  Po-Yuan Ke; Zee-Fen Chang
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.

Authors:  J L Binet; A Auquier; G Dighiero; C Chastang; H Piguet; J Goasguen; G Vaugier; G Potron; P Colona; F Oberling; M Thomas; G Tchernia; C Jacquillat; P Boivin; C Lesty; M T Duault; M Monconduit; S Belabbes; F Gremy
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

View more
  7 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.

Authors:  Yin-Hua Wang; Zhi-Jian Zou; Ling Liu; Li-Na Zhang; Cheng Fang; Dan-Xia Zhu; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

Review 3.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

4.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

5.  Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.

Authors:  Zhi Heng Chen; Shou Qing Huang; Yande Wang; Ai Zhen Yang; Jian Wen; Xiao Hong Xu; Yan Chen; Qu Bo Chen; Ying Hong Wang; Ellen He; Ji Zhou; Sven Skog
Journal:  Sensors (Basel)       Date:  2011-11-28       Impact factor: 3.576

6.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

7.  Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia.

Authors:  Marilisa Marinelli; Caterina Ilari; Yi Xia; Ilaria Del Giudice; Luciana Cafforio; Irene Della Starza; Sara Raponi; Paola Mariglia; Silvia Bonina; Zhen Yu; Wenjuan Yang; Lugui Qiu; Thomas Chan; Alfonso Piciocchi; Yok-Lam Kwong; Eric Tse; Jianyong Li; Anna Guarini; Wei Xu; Robin Foà
Journal:  Oncotarget       Date:  2016-04-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.